Product Description — Luxdegalutamide (ARV-766)
Luxdegalutamide (ARV-766), also known as JSB462, is a potent, orally bioavailable androgen receptor (AR)-targeted PROTAC (Proteolysis-Targeting Chimera) protein degrader. Its chemical name is 4-(4-((1-(4-(((1R,3R)-3-(4-cyano-3-methoxyphenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-N-((S)-2,6-dioxopiperidin-3-yl)-2-fluorobenzamide. Luxdegalutamide is designed to induce proximity between the androgen receptor and the Cereblon (CRBN) E3 ubiquitin ligase, promoting ubiquitination and subsequent proteasomal degradation of AR. This targeted degradation mechanism makes ARV-766 a valuable research compound for studying AR signaling, protein degradation pathways, and AR-driven cancer biology.
Product Specifications: CAS No. 2750830-09-0; molecular formula C₄₅H₅₄FN₇O₆; molecular weight 807.95 g/mol. Luxdegalutamide has been investigated as an AR degrader capable of targeting wild-type AR as well as clinically relevant AR ligand-binding-domain mutations, including L702H, H875Y, and T878A. It can therefore be used as a research tool in studies of androgen receptor signaling, AR mutation-associated resistance mechanisms, targeted protein degradation, and prostate cancer models.
Usage & Precautions: Luxdegalutamide is intended for research use only and is not intended for human or veterinary use, diagnosis, treatment, or prevention of disease. Researchers should handle the compound according to appropriate laboratory safety procedures and consult the product-specific SDS and Certificate of Analysis (COA) before use. The compound is reported to be insoluble in water and ethanol and soluble in DMSO; actual solubility may vary depending on experimental conditions. Store the product according to the conditions specified on the product label or COA and protect it from moisture, excessive heat, and direct light. Appropriate personal protective equipment (PPE), including gloves, protective clothing, and eye protection, should be used during handling.
关键字： PROTAC;AR degrader;Prostate Cancer;Drug Discovery;
杭州埃米尔生物技术有限公司位于浙江省杭州市钱塘区下沙街道安和药谷，立足杭州生物医药产业集聚区位优势，专注深耕ADC/XDC 生物偶联技术研发服务、医药小分子中间体定制合成两大核心业务，是聚焦抗体偶联药物上下游研发配套的专业化生物技术初创企业，面向药企、CRO 公司、高校科研院所提供从工艺开发、样品合成到质控分析的一站式技术外包解决方案。